The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The need to improve management and treatment strategies for secondary CNS lymphoma
Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, briefly discusses the need to improve treatment approaches for secondary CNS lymphoma. Dr Roschewski explains that the main approach to this disease involves prevention with methotrexate, which is ineffective in many cases, and emphasizes the need for novel treatment strategies. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
